NCT07487519: Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Sponsor: Shanghai Henlius Biotech. Phase: PHASE2. Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC))